| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
26,924 |
20,019 |
$1.24M |
| 64450 |
|
18,659 |
9,942 |
$994K |
| J3490 |
Unclassified drugs |
19,727 |
9,773 |
$946K |
| 76942 |
|
12,279 |
9,213 |
$265K |
| 20553 |
|
14,506 |
9,856 |
$198K |
| L0648 |
Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
655 |
543 |
$169K |
| 64418 |
|
5,036 |
3,247 |
$147K |
| 64483 |
|
1,639 |
1,355 |
$130K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,249 |
1,120 |
$92K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
1,213 |
1,113 |
$90K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
2,361 |
600 |
$90K |
| 95913 |
|
502 |
433 |
$64K |
| 64484 |
|
1,645 |
1,351 |
$54K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
1,671 |
429 |
$44K |
| E0745 |
Neuromuscular stimulator, electronic shock unit |
174 |
144 |
$36K |
| 62321 |
|
577 |
456 |
$36K |
| 77003 |
|
4,401 |
3,109 |
$35K |
| 95886 |
|
566 |
474 |
$31K |
| 95887 |
|
566 |
449 |
$23K |
| 97124 |
|
8,510 |
4,480 |
$19K |
| 62323 |
|
358 |
267 |
$18K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
3,857 |
1,974 |
$18K |
| 64493 |
|
311 |
232 |
$17K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
4,163 |
2,739 |
$15K |
| E0731 |
Form fitting conductive garment for delivery of tens or nmes (with conductive fibers separated from the patient's skin by layers of fabric) |
162 |
140 |
$14K |
| 20610 |
|
735 |
499 |
$12K |
| 64405 |
|
5,806 |
2,648 |
$11K |
| 64495 |
|
334 |
245 |
$11K |
| Q4206 |
Fluid flow or fluid gf, 1 cc |
20 |
18 |
$10K |
| 64494 |
|
300 |
232 |
$9K |
| 80305 |
|
1,349 |
1,245 |
$8K |
| 72275 |
|
156 |
154 |
$7K |
| 97161 |
|
314 |
228 |
$4K |
| 95912 |
|
30 |
30 |
$4K |
| 95911 |
|
25 |
25 |
$4K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
36 |
33 |
$4K |
| 77002 |
|
97 |
87 |
$4K |
| 72100 |
|
83 |
83 |
$2K |
| G0281 |
Electrical stimulation, (unattended), to one or more areas, for chronic stage iii and stage iv pressure ulcers, arterial ulcers, diabetic ulcers, and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care, as part of a therapy plan of care |
903 |
259 |
$2K |
| 72040 |
|
71 |
71 |
$1K |
| 64635 |
|
13 |
12 |
$1K |
| 96130 |
|
145 |
79 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
293 |
170 |
$1K |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
763 |
206 |
$824.11 |
| 64636 |
|
13 |
12 |
$780.76 |
| 97014 |
|
355 |
71 |
$581.66 |
| 73560 |
|
21 |
12 |
$387.98 |
| 99443 |
|
14 |
14 |
$271.04 |
| 97750 |
|
50 |
47 |
$221.95 |
| 96136 |
|
149 |
80 |
$214.98 |
| 99358 |
Prolong nursin fac eval 15m |
72 |
70 |
$136.34 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
283 |
266 |
$89.47 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
553 |
362 |
$36.01 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
226 |
217 |
$14.09 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
75 |
62 |
$1.12 |
| G0460 |
Autologous platelet rich plasma or other blood-derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration and dressings, per treatment |
78 |
14 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
149 |
114 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
38 |
30 |
$0.00 |